Overview

• Stanford Medicine researchers confirm that CAR-T cell therapy can independently cause mild cognitive impairments, known as 'brain fog.'
• The impairments stem from microglial activation, which damages oligodendrocytes and myelin, disrupting brain function.
• Mouse studies show that transient microglia depletion or chemokine receptor blockade can reverse these cognitive deficits.
• Human postmortem brain tissue shows similar neuroimmune changes, supporting the findings from animal models.
• The study highlights actionable therapeutic targets to mitigate cognitive side effects and improve quality of life for cancer survivors.